Phase 1b Study of SAR650984 in Combo with Lenalidomide and Dexa for Treatment of Relapsed or Refractory Multiple Myeloma

Investigator: Thomas G. Martin, MD
Sponsor: Sanofi-Aventis Group

Location(s): United States


The study duration for an individual patient will include a screening period for inclusion of up to 21 days, and at least 4 weeks of treatment in the absence of severe adverse reaction, dose limiting toxicity or disease progression plus up to 60 days post-treatment follow up.